The HALT polycystic kidney disease trials

Design and implementation

Arlene B. Chapman, Vicente Torres, Ronald D. Perrone, Theodore I. Steinman, Kyongtae T. Bae, J. Philip Miller, Dana C. Miskulin, Frederic Rahbari Oskoui, Amirali Masoumi, Marie C Hogan, Franz T. Winklhofer, William Braun, Paul A. Thompson, Catherine M. Meyers, Cass Kelleher, Robert W. Schrier

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Background and objectives: Two HALT PKD trials will investigate interventions that potentially slow kidney disease progression in hypertensive autosomal dominant polycystic kidney disease (ADPKD) patients. Studies were designed in early and later stages of ADPKD to assess the impact of intensive blockade of the renin-angiotensin-aldosterone system and level of BP control on progressive renal disease. Design, settings, participants, and measurements: PKD-HALT trials are multicenter, randomized, double-blind, placebocontrolled trials studying 1018 hypertensive ADPKD patients enrolled over 3 yr with 4 to 8 yr of follow-up. In study A, 548 participants, estimated GFR (eGFR) of >60 ml/min per 1.73 m2 were randomized to one of four arms in a 2-by-2 design: combination angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) therapy versus ACEi monotherapy at two levels of BP control. In study B, 470 participants, eGFR of 25 to 60 ml/min per 1.73 m 2 compared ACEi/ARB therapy versus ACEi monotherapy, with BP control of 120 to 130/70 to 80 mmHg. Primary outcomes of studies A and B are MR-based percent change kidney volume and a composite endpoint of time to 50% reduction of baseline estimated eGFR, ESRD, or death, respectively. Results: This report describes design issues related to (1) novel endpoints such as kidney volume, (2) home versus office BP measures, and (3) the impact of RAAS inhibition on kidney and patient outcomes, safety, and quality of life. Conclusions: HALT PKD will evaluate potential benefits of rigorous BP control and inhibition of the renin-angiotensinaldosterone system on kidney disease progression in ADPKD.

Original languageEnglish (US)
Pages (from-to)102-109
Number of pages8
JournalClinical Journal of the American Society of Nephrology
Volume5
Issue number1
DOIs
StatePublished - 2010

Fingerprint

Autosomal Dominant Polycystic Kidney
Polycystic Kidney Diseases
Angiotensin-Converting Enzyme Inhibitors
Kidney
Angiotensin Receptor Antagonists
Kidney Diseases
Disease Progression
Patient Safety
Renin-Angiotensin System
Renin
Multicenter Studies
Chronic Kidney Failure
Quality of Life
Outcome Assessment (Health Care)
Therapeutics

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Chapman, A. B., Torres, V., Perrone, R. D., Steinman, T. I., Bae, K. T., Philip Miller, J., ... Schrier, R. W. (2010). The HALT polycystic kidney disease trials: Design and implementation. Clinical Journal of the American Society of Nephrology, 5(1), 102-109. https://doi.org/10.2215/CJN.04310709

The HALT polycystic kidney disease trials : Design and implementation. / Chapman, Arlene B.; Torres, Vicente; Perrone, Ronald D.; Steinman, Theodore I.; Bae, Kyongtae T.; Philip Miller, J.; Miskulin, Dana C.; Oskoui, Frederic Rahbari; Masoumi, Amirali; Hogan, Marie C; Winklhofer, Franz T.; Braun, William; Thompson, Paul A.; Meyers, Catherine M.; Kelleher, Cass; Schrier, Robert W.

In: Clinical Journal of the American Society of Nephrology, Vol. 5, No. 1, 2010, p. 102-109.

Research output: Contribution to journalArticle

Chapman, AB, Torres, V, Perrone, RD, Steinman, TI, Bae, KT, Philip Miller, J, Miskulin, DC, Oskoui, FR, Masoumi, A, Hogan, MC, Winklhofer, FT, Braun, W, Thompson, PA, Meyers, CM, Kelleher, C & Schrier, RW 2010, 'The HALT polycystic kidney disease trials: Design and implementation', Clinical Journal of the American Society of Nephrology, vol. 5, no. 1, pp. 102-109. https://doi.org/10.2215/CJN.04310709
Chapman, Arlene B. ; Torres, Vicente ; Perrone, Ronald D. ; Steinman, Theodore I. ; Bae, Kyongtae T. ; Philip Miller, J. ; Miskulin, Dana C. ; Oskoui, Frederic Rahbari ; Masoumi, Amirali ; Hogan, Marie C ; Winklhofer, Franz T. ; Braun, William ; Thompson, Paul A. ; Meyers, Catherine M. ; Kelleher, Cass ; Schrier, Robert W. / The HALT polycystic kidney disease trials : Design and implementation. In: Clinical Journal of the American Society of Nephrology. 2010 ; Vol. 5, No. 1. pp. 102-109.
@article{8eb800e390964f7e9bb5abbf33f680f0,
title = "The HALT polycystic kidney disease trials: Design and implementation",
abstract = "Background and objectives: Two HALT PKD trials will investigate interventions that potentially slow kidney disease progression in hypertensive autosomal dominant polycystic kidney disease (ADPKD) patients. Studies were designed in early and later stages of ADPKD to assess the impact of intensive blockade of the renin-angiotensin-aldosterone system and level of BP control on progressive renal disease. Design, settings, participants, and measurements: PKD-HALT trials are multicenter, randomized, double-blind, placebocontrolled trials studying 1018 hypertensive ADPKD patients enrolled over 3 yr with 4 to 8 yr of follow-up. In study A, 548 participants, estimated GFR (eGFR) of >60 ml/min per 1.73 m2 were randomized to one of four arms in a 2-by-2 design: combination angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) therapy versus ACEi monotherapy at two levels of BP control. In study B, 470 participants, eGFR of 25 to 60 ml/min per 1.73 m 2 compared ACEi/ARB therapy versus ACEi monotherapy, with BP control of 120 to 130/70 to 80 mmHg. Primary outcomes of studies A and B are MR-based percent change kidney volume and a composite endpoint of time to 50{\%} reduction of baseline estimated eGFR, ESRD, or death, respectively. Results: This report describes design issues related to (1) novel endpoints such as kidney volume, (2) home versus office BP measures, and (3) the impact of RAAS inhibition on kidney and patient outcomes, safety, and quality of life. Conclusions: HALT PKD will evaluate potential benefits of rigorous BP control and inhibition of the renin-angiotensinaldosterone system on kidney disease progression in ADPKD.",
author = "Chapman, {Arlene B.} and Vicente Torres and Perrone, {Ronald D.} and Steinman, {Theodore I.} and Bae, {Kyongtae T.} and {Philip Miller}, J. and Miskulin, {Dana C.} and Oskoui, {Frederic Rahbari} and Amirali Masoumi and Hogan, {Marie C} and Winklhofer, {Franz T.} and William Braun and Thompson, {Paul A.} and Meyers, {Catherine M.} and Cass Kelleher and Schrier, {Robert W.}",
year = "2010",
doi = "10.2215/CJN.04310709",
language = "English (US)",
volume = "5",
pages = "102--109",
journal = "Clinical Journal of the American Society of Nephrology",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - The HALT polycystic kidney disease trials

T2 - Design and implementation

AU - Chapman, Arlene B.

AU - Torres, Vicente

AU - Perrone, Ronald D.

AU - Steinman, Theodore I.

AU - Bae, Kyongtae T.

AU - Philip Miller, J.

AU - Miskulin, Dana C.

AU - Oskoui, Frederic Rahbari

AU - Masoumi, Amirali

AU - Hogan, Marie C

AU - Winklhofer, Franz T.

AU - Braun, William

AU - Thompson, Paul A.

AU - Meyers, Catherine M.

AU - Kelleher, Cass

AU - Schrier, Robert W.

PY - 2010

Y1 - 2010

N2 - Background and objectives: Two HALT PKD trials will investigate interventions that potentially slow kidney disease progression in hypertensive autosomal dominant polycystic kidney disease (ADPKD) patients. Studies were designed in early and later stages of ADPKD to assess the impact of intensive blockade of the renin-angiotensin-aldosterone system and level of BP control on progressive renal disease. Design, settings, participants, and measurements: PKD-HALT trials are multicenter, randomized, double-blind, placebocontrolled trials studying 1018 hypertensive ADPKD patients enrolled over 3 yr with 4 to 8 yr of follow-up. In study A, 548 participants, estimated GFR (eGFR) of >60 ml/min per 1.73 m2 were randomized to one of four arms in a 2-by-2 design: combination angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) therapy versus ACEi monotherapy at two levels of BP control. In study B, 470 participants, eGFR of 25 to 60 ml/min per 1.73 m 2 compared ACEi/ARB therapy versus ACEi monotherapy, with BP control of 120 to 130/70 to 80 mmHg. Primary outcomes of studies A and B are MR-based percent change kidney volume and a composite endpoint of time to 50% reduction of baseline estimated eGFR, ESRD, or death, respectively. Results: This report describes design issues related to (1) novel endpoints such as kidney volume, (2) home versus office BP measures, and (3) the impact of RAAS inhibition on kidney and patient outcomes, safety, and quality of life. Conclusions: HALT PKD will evaluate potential benefits of rigorous BP control and inhibition of the renin-angiotensinaldosterone system on kidney disease progression in ADPKD.

AB - Background and objectives: Two HALT PKD trials will investigate interventions that potentially slow kidney disease progression in hypertensive autosomal dominant polycystic kidney disease (ADPKD) patients. Studies were designed in early and later stages of ADPKD to assess the impact of intensive blockade of the renin-angiotensin-aldosterone system and level of BP control on progressive renal disease. Design, settings, participants, and measurements: PKD-HALT trials are multicenter, randomized, double-blind, placebocontrolled trials studying 1018 hypertensive ADPKD patients enrolled over 3 yr with 4 to 8 yr of follow-up. In study A, 548 participants, estimated GFR (eGFR) of >60 ml/min per 1.73 m2 were randomized to one of four arms in a 2-by-2 design: combination angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) therapy versus ACEi monotherapy at two levels of BP control. In study B, 470 participants, eGFR of 25 to 60 ml/min per 1.73 m 2 compared ACEi/ARB therapy versus ACEi monotherapy, with BP control of 120 to 130/70 to 80 mmHg. Primary outcomes of studies A and B are MR-based percent change kidney volume and a composite endpoint of time to 50% reduction of baseline estimated eGFR, ESRD, or death, respectively. Results: This report describes design issues related to (1) novel endpoints such as kidney volume, (2) home versus office BP measures, and (3) the impact of RAAS inhibition on kidney and patient outcomes, safety, and quality of life. Conclusions: HALT PKD will evaluate potential benefits of rigorous BP control and inhibition of the renin-angiotensinaldosterone system on kidney disease progression in ADPKD.

UR - http://www.scopus.com/inward/record.url?scp=75749109803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749109803&partnerID=8YFLogxK

U2 - 10.2215/CJN.04310709

DO - 10.2215/CJN.04310709

M3 - Article

VL - 5

SP - 102

EP - 109

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

SN - 1555-9041

IS - 1

ER -